Targeting the IDH2 Pathway in Acute Myeloid Leukemia.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Maria L Amaya, Daniel A Pollyea

Abstract

Acute myeloid leukemia (AML) is an aggressive disease with a poor prognosis. A large percentage of patients succumb to this disease in spite of aggressive treatments with chemotherapy. Recent advances with mutational analysis led to the discovery of isocitrate dehydrogenase (IDH) mutations in AML. IDH2 is an enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate; its mutated version leads to the accumulation of the oncometabolite (R)-2 hydroxyglutarate, which disrupts several cell processes and leads to a blockage in differentiation. Targeting IDH2 is compelling, as it is an early and stable mutation in AML. Enasidenib, a specific small-molecule inhibitor of IDH2, recently gained FDA approval for the treatment of patients with relapsed/refractory IDH2-mutated AML. In this review, we will focus on the indications and efficacy of enasidenib in the treatment of patients with IDH2-mutated AML. Clin Cancer Res; 24(20); 4931-6. ©2018 AACR.

References

Oct 13, 2001·Science·R K Bruick, S L McKnight
Feb 27, 2007·Oncogene·J M Adams, S Cory
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Oct 29, 2008·Oncogene·K W Yip, J C Reed
Feb 21, 2009·The New England Journal of Medicine·Hai YanDarell D Bigner
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolas BoisselClaude Preudhomme
Oct 19, 2010·Haematologica·Gautam BorthakurJorge E Cortes
Dec 22, 2010·American Journal of Clinical Pathology·Keyur P PatelRajyalakshmi Luthra
Apr 5, 2011·EMBO Reports·Rasheduzzaman ChowdhuryAkane Kawamura
Jun 8, 2011·Leukemia·A K AnderssonJ R Downing
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Dec 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maxime JaninStéphane de Botton
May 29, 2015·American Journal of Hematology·Courtney D DiNardoHagop Kantarjian
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Nov 11, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eytan M Stein
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Mar 2, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qingyu XuLi Yu
Jun 8, 2017·Blood·Eytan M SteinMartin S Tallman

❮ Previous
Next ❯

Citations

Nov 7, 2019·International Journal of Cancer. Journal International Du Cancer·Anna P SokolenkoEvgeny N Imyanitov
Jun 4, 2020·International Journal of Molecular Sciences·Cristina PanuzzoDaniela Cilloni
Dec 19, 2019·Antioxidants & Redox Signaling·Petr Ježek
Oct 30, 2019·Biomarker Research·Xiaoyan Liu, Yuping Gong
Nov 9, 2020·Clinical Epigenetics·Ping Zhang, Mingzhi Zhang
Sep 19, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yuan WangDario C Altieri
Jul 30, 2020·Current Oncology Reports·Matt LechnerValerie J Lund
Sep 8, 2021·Nature Communications·Michael S HwangSandra B Gabelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved